BMY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

12.24B

-0.85%

1.644

-1.55%

10.58B

-5.52%

1.489

-17.28%

11.40B

-7.07%

1.606

+10.02%

Estimates Revision

The market is revising Upward the revenue expectations for Bristol-Myers Squibb Company (BMY) for FY2025, with the revenue forecasts being adjusted by 1.55% over the past three months. During the same period, the stock price has changed by 16.20%.

Revenue Estimates for FY2025

Revise Upward

+1.55%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.37%

In Past 3 Month

Stock Price

Go Up

+16.20%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast BMY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 52.67 USD with a low forecast of 36.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

11 Hold

1 Sell

Moderate Buy

Current: 53.860

Low

36.00

Averages

52.67

High

68.00

Current: 53.860

Low

36.00

Averages

52.67

High

68.00

BofA

Neutral -> Buy

upgrade

$52 -> $61

2025-12-15

New

Reason

BofA

Price Target

$52 -> $61

2025-12-15

New

upgrade

Neutral -> Buy

Reason

BofA upgraded Bristol Myers to Buy from Neutral with a price target of $61, up from $52.

BofA

Neutral -> Buy

upgrade

$52 -> $61

2025-12-15

New

Reason

BofA

Price Target

$52 -> $61

2025-12-15

New

upgrade

Neutral -> Buy

Reason

As previously reported, BofA upgraded Bristol Myers to Buy from Neutral with a price target of $61, up from $52, based on the strength of Bristol's R&D pipeline. The firm expects 4-6 programs to deliver key de-risking catalysts in the near-term and sees current weakness as a buying opportunity as conservative trough EPS provides a floor for share price and "good pharma pipeline stories can work once investors have visibility on the next product cycle," the analyst contends ahead of "a catalyst-rich 2026." The firm sees multiple scenarios that could position the company for return to growth in 2029 and beyond, the analyst added.

Guggenheim

Neutral -> Buy

upgrade

$62

2025-12-12

New

Reason

Guggenheim

Price Target

$62

2025-12-12

New

upgrade

Neutral -> Buy

Reason

As previously reported, Guggenheim upgraded Bristol Myers to Buy from Neutral with a $62 price target ahead of 2026, which the firm believes "offers a much more compelling value-oriented and pipeline-driven risk/reward." Given already low expectations for earnings and clinical readouts, the firm views the stock's 2026 floor to be "closer to $50/shr," the analyst tells investors. Meanwhile, recent developments together with ongoing deep dive work into FXI/a, LPA1 and sotatercept sales "offers an attractive (perhaps even compelling entry point) for yield-oriented value investors," the analyst argues.

Morgan Stanley

Underweight

maintain

$36 -> $37

2025-12-12

New

Reason

Morgan Stanley

Price Target

$36 -> $37

2025-12-12

New

maintain

Underweight

Reason

Morgan Stanley raised the firm's price target on Bristol Myers to $37 from $36 and keeps an Underweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

Guggenheim

Neutral -> Buy

upgrade

$62

2025-12-12

New

Reason

Guggenheim

Price Target

$62

2025-12-12

New

upgrade

Neutral -> Buy

Reason

Guggenheim upgraded Bristol Myers to Buy from Neutral with a $62 price target.

HSBC

Hold

maintain

$50 -> $53

2025-12-10

New

Reason

HSBC

Price Target

$50 -> $53

2025-12-10

New

maintain

Hold

Reason

HSBC raised the firm's price target on Bristol Myers to $53 from $50 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Valuation Metrics

The current forward P/E ratio for Bristol-Myers Squibb Co (BMY.N) is 8.44, compared to its 5-year average forward P/E of 11.31. For a more detailed relative valuation and DCF analysis to assess Bristol-Myers Squibb Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

11.31

Current PE

8.44

Overvalued PE

24.90

Undervalued PE

-2.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.00

Current EV/EBITDA

8.77

Overvalued EV/EBITDA

14.24

Undervalued EV/EBITDA

5.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.75

Current PS

2.35

Overvalued PS

3.28

Undervalued PS

2.21

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 15753.1% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 15753.1% over the last month.

Sold

Bought

BMY News & Events

Events Timeline

No data

News

6.0

13:44 PMCNBC

Monday's Top Analyst Recommendations: Nvidia, Tesla, Apple, Viking, Hershey, Marriott, Dollar General, and More

4.0

12:14 PMYahoo Finance

BofA Securities Raises Bristol-Myers Squibb Rating to Buy with a $61 Price Target

8.0

12-14Yahoo Finance

2 Dividend Stocks Worth Investing In Immediately

People Also Watch

Frequently Asked Questions

What is Bristol-Myers Squibb Co (BMY) stock price today?

The current price of BMY is 53.86 USD — it has increased 2.77 % in the last trading day.

What is Bristol-Myers Squibb Co (BMY)'s business?

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

What is the price predicton of BMY Stock?

What is Bristol-Myers Squibb Co (BMY)'s revenue for the last quarter?

Bristol-Myers Squibb Co revenue for the last quarter amounts to 12.22B USD, increased 2.77 % YoY.

What is Bristol-Myers Squibb Co (BMY)'s earnings per share (EPS) for the last quarter?

Bristol-Myers Squibb Co. EPS for the last quarter amounts to 1.08 USD, increased 80.00 % YoY.

What changes have occurred in the market's expectations for Bristol-Myers Squibb Co (BMY)'s fundamentals?

How many employees does Bristol-Myers Squibb Co (BMY). have?

Bristol-Myers Squibb Co (BMY) has 34100 emplpoyees as of December 15 2025.

What is Bristol-Myers Squibb Co (BMY) market cap?

Today BMY has the market capitalization of 106.69B USD.